172 related articles for article (PubMed ID: 37830151)
1. Targeting of STAT5 using the small molecule topotecan hydrochloride suppresses acute myeloid leukemia progression.
Li J; Tang B; Miao Y; Li G; Sun Z
Oncol Rep; 2023 Dec; 50(6):. PubMed ID: 37830151
[TBL] [Abstract][Full Text] [Related]
2. Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness.
Liu ACH; Cathelin S; Yang Y; Dai DL; Ayyathan DM; Hosseini M; Minden MD; Tierens A; Chan SM
Cancer Res; 2022 Dec; 82(23):4325-4339. PubMed ID: 36150062
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic inhibition of STAT5 in acute myeloid leukemia.
Wingelhofer B; Maurer B; Heyes EC; Cumaraswamy AA; Berger-Becvar A; de Araujo ED; Orlova A; Freund P; Ruge F; Park J; Tin G; Ahmar S; Lardeau CH; Sadovnik I; Bajusz D; Keserű GM; Grebien F; Kubicek S; Valent P; Gunning PT; Moriggl R
Leukemia; 2018 May; 32(5):1135-1146. PubMed ID: 29472718
[TBL] [Abstract][Full Text] [Related]
4. Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells.
Tong H; Ren Y; Zhang F; Jin J
Eur J Haematol; 2008 Oct; 81(4):259-66. PubMed ID: 18616510
[TBL] [Abstract][Full Text] [Related]
5. Abivertinib, a novel BTK inhibitor: Anti-Leukemia effects and synergistic efficacy with homoharringtonine in acute myeloid leukemia.
Huang S; Pan J; Jin J; Li C; Li X; Huang J; Huang X; Yan X; Li F; Yu M; Hu C; Jin J; Xu Y; Ling Q; Ye W; Wang Y; Jin J
Cancer Lett; 2019 Oct; 461():132-143. PubMed ID: 31310800
[TBL] [Abstract][Full Text] [Related]
6. SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism.
Polak A; Bialopiotrowicz E; Krzymieniewska B; Wozniak J; Stojak M; Cybulska M; Kaniuga E; Mikula M; Jablonska E; Gorniak P; Noyszewska-Kania M; Szydlowski M; Piechna K; Piwocka K; Bugajski L; Lech-Maranda E; Barankiewicz J; Kolkowska-Lesniak A; Patkowska E; Glodkowska-Mrowka E; Baran N; Juszczynski P
Cell Death Dis; 2020 Nov; 11(11):956. PubMed ID: 33159047
[TBL] [Abstract][Full Text] [Related]
7. Aberrantly low STAT3 and STAT5 responses are associated with poor outcome and an inflammatory gene expression signature in pediatric acute myeloid leukemia.
Narayanan P; Man TK; Gerbing RB; Ries R; Stevens AM; Wang YC; Long X; Gamis AS; Cooper T; Meshinchi S; Alonzo TA; Redell MS
Clin Transl Oncol; 2021 Oct; 23(10):2141-2154. PubMed ID: 33948920
[TBL] [Abstract][Full Text] [Related]
8. Rationale for a Combination Therapy with the STAT5 Inhibitor AC-4-130 and the MCL1 Inhibitor S63845 in the Treatment of FLT3-Mutated or TET2-Mutated Acute Myeloid Leukemia.
Seipel K; Graber C; Flückiger L; Bacher U; Pabst T
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360855
[TBL] [Abstract][Full Text] [Related]
9. Spermatogenesis associated serine rich 2 like plays a prognostic factor and therapeutic target in acute myeloid leukemia by regulating the JAK2/STAT3/STAT5 axis.
Li F; Ye W; Yao Y; Wei W; Lin X; Zhuang H; Li C; Li X; Ling Q; Hu C; Huang X; Qian Y; Mao S; Huang J; Lu Y; Jin J
J Transl Med; 2023 Feb; 21(1):115. PubMed ID: 36774517
[TBL] [Abstract][Full Text] [Related]
10. CD82 regulates STAT5/IL-10 and supports survival of acute myelogenous leukemia cells.
Nishioka C; Ikezoe T; Yang J; Nobumoto A; Kataoka S; Tsuda M; Udaka K; Yokoyama A
Int J Cancer; 2014 Jan; 134(1):55-64. PubMed ID: 23797738
[TBL] [Abstract][Full Text] [Related]
11. FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia.
Nogami A; Oshikawa G; Okada K; Fukutake S; Umezawa Y; Nagao T; Kurosu T; Miura O
Oncotarget; 2015 Apr; 6(11):9189-205. PubMed ID: 25826077
[TBL] [Abstract][Full Text] [Related]
12. STAT5: From Pathogenesis Mechanism to Therapeutic Approach in Acute Leukemia.
Shahjahani M; Abroun A; Saki N; Bagher Mohammadi SM; Rezaeeyan H
Lab Med; 2020 Jul; 51(4):345-351. PubMed ID: 31860086
[TBL] [Abstract][Full Text] [Related]
13. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.
Spiekermann K; Bagrintseva K; Schwab R; Schmieja K; Hiddemann W
Clin Cancer Res; 2003 Jun; 9(6):2140-50. PubMed ID: 12796379
[TBL] [Abstract][Full Text] [Related]
14. Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib
Dumas PY; Naudin C; Martin-Lannerée S; Izac B; Casetti L; Mansier O; Rousseau B; Artus A; Dufossée M; Giese A; Dubus P; Pigneux A; Praloran V; Bidet A; Villacreces A; Guitart A; Milpied N; Kosmider O; Vigon I; Desplat V; Dusanter-Fourt I; Pasquet JM
Haematologica; 2019 Oct; 104(10):2017-2027. PubMed ID: 30923103
[TBL] [Abstract][Full Text] [Related]
15. The Multi-kinase Inhibitor Debio 0617B Reduces Maintenance and Self-renewal of Primary Human AML CD34
Murone M; Radpour R; Attinger A; Chessex AV; Huguenin AL; Schürch CM; Banz Y; Sengupta S; Aguet M; Rigotti S; Bachhav Y; Massière F; Ramachandra M; McAllister A; Riether C
Mol Cancer Ther; 2017 Aug; 16(8):1497-1510. PubMed ID: 28468777
[TBL] [Abstract][Full Text] [Related]
16. FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation.
Yoshimoto G; Miyamoto T; Jabbarzadeh-Tabrizi S; Iino T; Rocnik JL; Kikushige Y; Mori Y; Shima T; Iwasaki H; Takenaka K; Nagafuji K; Mizuno S; Niiro H; Gilliland GD; Akashi K
Blood; 2009 Dec; 114(24):5034-43. PubMed ID: 19808698
[TBL] [Abstract][Full Text] [Related]
17. Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells.
Cook AM; Li L; Ho Y; Lin A; Li L; Stein A; Forman S; Perrotti D; Jove R; Bhatia R
Blood; 2014 May; 123(18):2826-37. PubMed ID: 24668492
[TBL] [Abstract][Full Text] [Related]
18. Aurora kinase inhibitor restrains STAT5-activated leukemic cell proliferation by inducing mitochondrial impairment.
Wang JX; Zhang L; Huang ZW; Zhang XN; Jiang YY; Liu FJ; Long L; Xue MJ; Lu G; Liu Q; Long ZJ
J Cell Physiol; 2020 Nov; 235(11):8358-8370. PubMed ID: 32239704
[TBL] [Abstract][Full Text] [Related]
19. AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.
Barbarroja N; Torres LA; Rodriguez-Ariza A; Valverde-Estepa A; Lopez-Sanchez LM; Ruiz-Limon P; Perez-Sanchez C; Carretero RM; Velasco F; López-Pedrera C
Exp Hematol; 2010 Aug; 38(8):641-52. PubMed ID: 20380868
[TBL] [Abstract][Full Text] [Related]
20. SEL120-34A is a novel CDK8 inhibitor active in AML cells with high levels of serine phosphorylation of STAT1 and STAT5 transactivation domains.
Rzymski T; Mikula M; Żyłkiewicz E; Dreas A; Wiklik K; Gołas A; Wójcik K; Masiejczyk M; Wróbel A; Dolata I; Kitlińska A; Statkiewicz M; Kuklinska U; Goryca K; Sapała Ł; Grochowska A; Cabaj A; Szajewska-Skuta M; Gabor-Worwa E; Kucwaj K; Białas A; Radzimierski A; Combik M; Woyciechowski J; Mikulski M; Windak R; Ostrowski J; Brzózka K
Oncotarget; 2017 May; 8(20):33779-33795. PubMed ID: 28422713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]